CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: BPNT1 (ImmuneEditome ID:10380)

1. Gene summary of enriched editing regions for BPNT1

check button Gene summary
Gene informationGene symbol

BPNT1

Gene ID

10380

GeneSynonymsHEL20|PIP
GeneCytomap

1q41

GeneTypeprotein-coding
GeneDescription3'(2'),5'-bisphosphate nucleotidase 1|BPntase|PAP-inositol-1,4-phosphatase|bisphosphate 3'-nucleotidase 1|epididymis luminal protein 20|testicular tissue protein Li 29
GeneModificationdate20230517
UniprotIDO95861;F8VRY7;F8W1J0;F8VVW8;F8VZG4;A6NF51
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:220057885-220059362:-ENST00000322067.10ENSG00000162813.16BPNT1exonicAluY,AluSc,AluJo,AluSzchr1:220057885-220059362:-.alignment
chr1:220057885-220059362:-ENST00000354807.6ENSG00000162813.16BPNT1exonicAluY,AluSc,AluJo,AluSzchr1:220057885-220059362:-.alignment
chr1:220057885-220059362:-ENST00000414869.5ENSG00000162813.16BPNT1exonicAluY,AluSc,AluJo,AluSzchr1:220057885-220059362:-.alignment
chr1:220057885-220059362:-ENST00000469520.5ENSG00000162813.16BPNT1exonicAluY,AluSc,AluJo,AluSzchr1:220057885-220059362:-.alignment
chr1:220057885-220059362:-ENST00000544404.4ENSG00000162813.16BPNT1exonicAluY,AluSc,AluJo,AluSzchr1:220057885-220059362:-.alignment


Top

2. Tumor-specific enriched editing regions for BPNT1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:220057885-220059362:-KICHEER3.9763e-05image
ENSG00000162813.16,BPNT1KICHEAG3.9763e-05image
chr1:220057885-220059362:-KIRCEER2.7098e-05image
ENSG00000162813.16,BPNT1KIRCEAG2.8281e-05image
chr1:220057885-220059362:-KIRPEER1.2792e-08image
ENSG00000162813.16,BPNT1KIRPEAG1.2792e-08image
chr1:220057885-220059362:-LUSCEER7.9772e-03image
ENSG00000162813.16,BPNT1LUSCEAG8.6110e-03image
chr1:220057885-220059362:-PRADEER2.3937e-03image
ENSG00000162813.16,BPNT1PRADEAG2.3937e-03image
chr1:220057885-220059362:-STADEER1.9582e-03image
ENSG00000162813.16,BPNT1STADEAG1.4871e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for BPNT1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:220057885-220059362:-CESCEERENSG00000241431,RPL37P60.31131.3103e-058.2482e-160.4398imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-COADEERENSG00000198740,ZNF6520.26701.0879e-031.5305e-150.4615imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000271916,RP11-884K10.60.25141.9933e-037.9986e-130.4191imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000237877,LINC014730.23883.7301e-033.8234e-130.4244imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr1:220057885-220059362:-COADEERENSG00000279265,AC000123.30.24083.8171e-031.0526e-130.4335imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000114739,ACVR2B0.23904.4619e-031.0489e-120.4171imageNNNAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:220057885-220059362:-COADEERENSG00000108306,FBXL200.23604.9508e-032.6189e-120.4103imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000202198,RN7SK0.23415.0369e-034.4480e-150.4547imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000196295,AC005154.60.22785.7632e-034.8158e-120.4058imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000230177,RP5-1112D6.40.23105.8950e-039.5258e-120.4005imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-CESCEERENSG00000241431,RPL37P60.31131.3103e-058.2482e-160.4398imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-COADEERENSG00000198740,ZNF6520.26701.0879e-031.5305e-150.4615imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000271916,RP11-884K10.60.25141.9933e-037.9986e-130.4191imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000237877,LINC014730.23883.7301e-033.8234e-130.4244imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr1:220057885-220059362:-COADEERENSG00000279265,AC000123.30.24083.8171e-031.0526e-130.4335imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000114739,ACVR2B0.23904.4619e-031.0489e-120.4171imageNNNAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:220057885-220059362:-COADEERENSG00000108306,FBXL200.23604.9508e-032.6189e-120.4103imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000202198,RN7SK0.23415.0369e-034.4480e-150.4547imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000196295,AC005154.60.22785.7632e-034.8158e-120.4058imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000230177,RP5-1112D6.40.23105.8950e-039.5258e-120.4005imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-CESCEERENSG00000241431,RPL37P60.31131.3103e-058.2482e-160.4398imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-COADEERENSG00000198740,ZNF6520.26701.0879e-031.5305e-150.4615imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000271916,RP11-884K10.60.25141.9933e-037.9986e-130.4191imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000237877,LINC014730.23883.7301e-033.8234e-130.4244imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr1:220057885-220059362:-COADEERENSG00000279265,AC000123.30.24083.8171e-031.0526e-130.4335imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000114739,ACVR2B0.23904.4619e-031.0489e-120.4171imageNNNAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:220057885-220059362:-COADEERENSG00000108306,FBXL200.23604.9508e-032.6189e-120.4103imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000202198,RN7SK0.23415.0369e-034.4480e-150.4547imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000196295,AC005154.60.22785.7632e-034.8158e-120.4058imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000230177,RP5-1112D6.40.23105.8950e-039.5258e-120.4005imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-CESCEERENSG00000241431,RPL37P60.31131.3103e-058.2482e-160.4398imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-COADEERENSG00000198740,ZNF6520.26701.0879e-031.5305e-150.4615imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000271916,RP11-884K10.60.25141.9933e-037.9986e-130.4191imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000237877,LINC014730.23883.7301e-033.8234e-130.4244imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr1:220057885-220059362:-COADEERENSG00000279265,AC000123.30.24083.8171e-031.0526e-130.4335imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000114739,ACVR2B0.23904.4619e-031.0489e-120.4171imageNNNAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:220057885-220059362:-COADEERENSG00000108306,FBXL200.23604.9508e-032.6189e-120.4103imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000202198,RN7SK0.23415.0369e-034.4480e-150.4547imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000196295,AC005154.60.22785.7632e-034.8158e-120.4058imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000230177,RP5-1112D6.40.23105.8950e-039.5258e-120.4005imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-CESCEERENSG00000241431,RPL37P60.31131.3103e-058.2482e-160.4398imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-COADEERENSG00000198740,ZNF6520.26701.0879e-031.5305e-150.4615imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000271916,RP11-884K10.60.25141.9933e-037.9986e-130.4191imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000237877,LINC014730.23883.7301e-033.8234e-130.4244imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr1:220057885-220059362:-COADEERENSG00000279265,AC000123.30.24083.8171e-031.0526e-130.4335imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000114739,ACVR2B0.23904.4619e-031.0489e-120.4171imageNNNAEosinophilsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr1:220057885-220059362:-COADEERENSG00000108306,FBXL200.23604.9508e-032.6189e-120.4103imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000202198,RN7SK0.23415.0369e-034.4480e-150.4547imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_UP
chr1:220057885-220059362:-COADEERENSG00000196295,AC005154.60.22785.7632e-034.8158e-120.4058imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr1:220057885-220059362:-COADEERENSG00000230177,RP5-1112D6.40.23105.8950e-039.5258e-120.4005imageNNNAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

4. Enriched editing regions and immune related splicing for BPNT1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:220057885-220059362:-
CESCEERMEXENSG00000204628.7chr5181237019:181237042:181237586:181237694:181241491:181242345:181243691:1812438910.31041.1929e-047.9036e-160.4400imageNNGNB2L1B_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000162813.16,BPNT1
CESCEAGMEXENSG00000174851.10chr1166284915:66284966:66285700:66285758:66288080:66288292:66288954:662890070.29265.0100e-042.2637e-140.4193imageNBUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;LARP4B;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000162813.16,BPNT1
CESCEAGMEXENSG00000204628.7chr5181237019:181237042:181237600:181237694:181241491:181242345:181243691:1812438910.29055.5406e-043.6387e-150.4308imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184GNB2L1B_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-
CESCEERMEXENSG00000174851.10chr1166284915:66284966:66285700:66285758:66288080:66288292:66288954:662890070.29474.7005e-042.0447e-140.4199imageNNNAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-
CESCEERMEXENSG00000204628.7chr5181237019:181237042:181237600:181237694:181241491:181242345:181243691:1812438910.29215.3277e-044.1481e-150.4300imageNNGNB2L1B_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000162813.16,BPNT1
CESCEAGMEXENSG00000137154.8chr919376493:19376589:19378367:19378514:19379500:19379618:19380189:193802360.28198.0884e-041.8474e-150.4349imageNACIN1;ADAR;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184RPS6B_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-
CESCEERMEXENSG00000137154.8chr919376493:19376589:19378367:19378514:19379500:19379618:19380189:193802360.28337.9553e-041.8299e-150.4350imageNNRPS6B_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-
CESCEERIRENSG00000161921.10chr174733525:4734479:4734582:47346520.26013.9557e-032.0895e-130.4053imageNNCXCL16B_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-
CESCEERA3ENSG00000142208.11chr14104770744:104770823:104769391:104769626:104769391:1047704200.25905.1242e-036.9608e-150.4267imageNNAKT1B_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:220057885-220059362:-
CESCEERA3ENSG00000136908.13chr9127936552:127936655:127935098:127935314:127935098:1279357800.22736.5130e-031.4104e-130.4073imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for BPNT1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:220057885-220059362:-ACCEERNK_cells_activated2.5522e-020.2545image
ENSG00000162813.16,BPNT1ACCEAGNK_cells_activated2.5522e-020.2545image
chr1:220057885-220059362:-BLCAEERT_cells_regulatory_(Tregs)5.6224e-030.1374image
ENSG00000162813.16,BPNT1BLCAEAGT_cells_regulatory_(Tregs)5.0924e-030.1389image
chr1:220057885-220059362:-BRCAEERMast_cells_activated7.0824e-030.0819image
ENSG00000162813.16,BPNT1BRCAEAGMast_cells_activated6.8010e-030.0823image
chr1:220057885-220059362:-CESCEERMacrophages_M14.4080e-03-0.1629image
ENSG00000162813.16,BPNT1CESCEAGMacrophages_M13.6341e-03-0.1663image
chr1:220057885-220059362:-COADEEREosinophils8.9191e-030.1595image
ENSG00000162813.16,BPNT1COADEAGEosinophils8.9191e-030.1595image
chr1:220057885-220059362:-DLBCEERNK_cells_activated3.1604e-030.4174image
ENSG00000162813.16,BPNT1DLBCEAGNK_cells_activated3.1733e-030.4172image
chr1:220057885-220059362:-ESCAEERT_cells_regulatory_(Tregs)1.5328e-03-0.2477image
ENSG00000162813.16,BPNT1ESCAEAGT_cells_regulatory_(Tregs)1.5282e-03-0.2478image
chr1:220057885-220059362:-GBMEERMacrophages_M14.2659e-030.2201image
ENSG00000162813.16,BPNT1GBMEAGMacrophages_M14.2659e-030.2201image
chr1:220057885-220059362:-HNSCEERPlasma_cells3.3412e-020.0952image
ENSG00000162813.16,BPNT1HNSCEAGPlasma_cells3.2762e-020.0956image
chr1:220057885-220059362:-KIRCEERT_cells_regulatory_(Tregs)2.2608e-040.1874image
ENSG00000162813.16,BPNT1KIRCEAGT_cells_regulatory_(Tregs)2.2608e-040.1874image
chr1:220057885-220059362:-KIRPEERNK_cells_activated1.2229e-020.1475image
ENSG00000162813.16,BPNT1KIRPEAGNK_cells_activated1.2229e-020.1475image
chr1:220057885-220059362:-LGGEERMacrophages_M22.6324e-020.0966image
ENSG00000162813.16,BPNT1LGGEAGMacrophages_M22.7317e-020.0960image
chr1:220057885-220059362:-LIHCEERDendritic_cells_resting2.0904e-04-0.1909image
ENSG00000162813.16,BPNT1LIHCEAGDendritic_cells_resting3.1219e-04-0.1857image
chr1:220057885-220059362:-LUSCEERB_cells_memory6.3487e-030.1223image
ENSG00000162813.16,BPNT1LUSCEAGB_cells_memory6.0347e-030.1230image
chr1:220057885-220059362:-MESOEERB_cells_memory4.7677e-050.4334image
ENSG00000162813.16,BPNT1MESOEAGB_cells_memory4.1974e-050.4362image
chr1:220057885-220059362:-OVEERMacrophages_M21.8992e-02-0.1372image
ENSG00000162813.16,BPNT1OVEAGMacrophages_M22.7176e-02-0.1293image
chr1:220057885-220059362:-PAADEERNK_cells_resting4.8182e-040.2597image
ENSG00000162813.16,BPNT1PAADEAGNK_cells_resting7.5436e-040.2509image
chr1:220057885-220059362:-PCPGEERPlasma_cells1.4811e-020.1799image
ENSG00000162813.16,BPNT1PCPGEAGPlasma_cells1.8674e-020.1737image
chr1:220057885-220059362:-PRADEERT_cells_CD4_memory_resting1.5672e-04-0.1688image
ENSG00000162813.16,BPNT1PRADEAGT_cells_CD4_memory_resting1.5672e-04-0.1688image
chr1:220057885-220059362:-READEERMast_cells_activated1.2372e-02-0.2557image
ENSG00000162813.16,BPNT1READEAGMast_cells_activated1.2372e-02-0.2557image
chr1:220057885-220059362:-SARCEEREosinophils2.8477e-020.1367image
ENSG00000162813.16,BPNT1SARCEAGEosinophils2.7102e-020.1379image
chr1:220057885-220059362:-SKCMEERMacrophages_M11.0514e-02-0.1187image
ENSG00000162813.16,BPNT1SKCMEAGMacrophages_M11.1348e-02-0.1175image
chr1:220057885-220059362:-STADEEREosinophils3.5104e-080.2829image
ENSG00000162813.16,BPNT1STADEAGEosinophils2.7264e-080.2851image
chr1:220057885-220059362:-TGCTEERMacrophages_M24.9370e-03-0.2240image
ENSG00000162813.16,BPNT1TGCTEAGMacrophages_M25.9659e-03-0.2192image
chr1:220057885-220059362:-THCAEERNK_cells_activated4.3218e-050.1811image
ENSG00000162813.16,BPNT1THCAEAGNK_cells_activated4.1490e-050.1815image
chr1:220057885-220059362:-THYMEERMacrophages_M11.1793e-04-0.3471image
ENSG00000162813.16,BPNT1THYMEAGMacrophages_M11.1709e-04-0.3472image
chr1:220057885-220059362:-UCECEERNK_cells_activated4.2165e-020.1542image
ENSG00000162813.16,BPNT1UCECEAGNK_cells_activated4.5211e-020.1520image
chr1:220057885-220059362:-UCSEERMacrophages_M03.7826e-03-0.3808image
ENSG00000162813.16,BPNT1UCSEAGMacrophages_M03.7826e-03-0.3808image
chr1:220057885-220059362:-UVMEERPlasma_cells2.7252e-020.2718image
ENSG00000162813.16,BPNT1UVMEAGPlasma_cells2.7252e-020.2718image


Top

6. Enriched editing regions and immune gene sets for BPNT1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000162813.16,BPNT1COADEAG5.1374e-04-0.21081.0515e-02-0.15611.1285e-03-0.19797.6368e-03-0.1626image
chr1:220057885-220059362:-COADEER5.1374e-04-0.21081.0515e-02-0.15611.1285e-03-0.19797.6368e-03-0.1626image
ENSG00000162813.16,BPNT1KIRCEAG1.3231e-02-0.12652.6447e-02-0.11342.5588e-05-0.21334.2496e-03-0.1458image
chr1:220057885-220059362:-KIRCEER1.3231e-02-0.12652.6447e-02-0.11342.5588e-05-0.21334.2496e-03-0.1458image
ENSG00000162813.16,BPNT1LIHCEAG6.5174e-06-0.23113.3407e-07-0.26054.7677e-09-0.29733.1706e-02-0.1112image
chr1:220057885-220059362:-LIHCEER4.5563e-06-0.23481.7795e-07-0.26632.3490e-09-0.30292.6210e-02-0.1151image
ENSG00000162813.16,BPNT1TGCTEAG2.1066e-03-0.24443.6546e-03-0.23141.0158e-04-0.30623.1407e-02-0.1724image
chr1:220057885-220059362:-TGCTEER2.3564e-03-0.24184.5560e-03-0.22609.9891e-05-0.30643.2981e-02-0.1708image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr1:220057885-220059362:-ACCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.4801e-03-0.3561image
ENSG00000162813.16,BPNT1ACCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.4801e-03-0.3561image
chr1:220057885-220059362:-BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEER8.6211e-05-0.1938image
ENSG00000162813.16,BPNT1BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.9280e-05-0.1964image
ENSG00000162813.16,BPNT1BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.1704e-11-0.1960image
chr1:220057885-220059362:-BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0751e-10-0.1948image
ENSG00000162813.16,BPNT1CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.1042e-04-0.2014image
chr1:220057885-220059362:-CESCGSVA_HALLMARK_MITOTIC_SPINDLEEER3.7227e-04-0.2028image
ENSG00000162813.16,BPNT1CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEAG9.4901e-04-0.5342image
chr1:220057885-220059362:-CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEER9.4901e-04-0.5342image
ENSG00000162813.16,BPNT1COADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG6.5672e-07-0.2983image
chr1:220057885-220059362:-COADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER6.5672e-07-0.2983image
chr1:220057885-220059362:-DLBCGSVA_HALLMARK_PROTEIN_SECRETIONEER6.2901e-05-0.5446image
ENSG00000162813.16,BPNT1DLBCGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.9860e-05-0.5459image
chr1:220057885-220059362:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.2466e-040.2798image
ENSG00000162813.16,BPNT1ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.3409e-040.2792image
chr1:220057885-220059362:-GBMGSVA_HALLMARK_PROTEIN_SECRETIONEER9.8128e-04-0.2528image
ENSG00000162813.16,BPNT1GBMGSVA_HALLMARK_PROTEIN_SECRETIONEAG9.8128e-04-0.2528image
chr1:220057885-220059362:-HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.1896e-07-0.2343image
ENSG00000162813.16,BPNT1HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.8201e-07-0.2310image
chr1:220057885-220059362:-KICHGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.7742e-02-0.2603image
ENSG00000162813.16,BPNT1KICHGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.7742e-02-0.2603image
chr1:220057885-220059362:-KIRCGSVA_HALLMARK_UV_RESPONSE_DNEER6.4062e-08-0.2720image
ENSG00000162813.16,BPNT1KIRCGSVA_HALLMARK_UV_RESPONSE_DNEAG6.4062e-08-0.2720image
chr1:220057885-220059362:-KIRPGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.1771e-07-0.2958image
ENSG00000162813.16,BPNT1KIRPGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.1771e-07-0.2958image
chr1:220057885-220059362:-LGGGSVA_HALLMARK_UV_RESPONSE_DNEER1.2841e-07-0.2271image
ENSG00000162813.16,BPNT1LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG1.3132e-07-0.2270image
chr1:220057885-220059362:-LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.4765e-17-0.4222image
ENSG00000162813.16,BPNT1LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG7.1129e-17-0.4140image
ENSG00000162813.16,BPNT1LUADGSVA_HALLMARK_PEROXISOMEEAG8.7766e-04-0.1467image
chr1:220057885-220059362:-LUADGSVA_HALLMARK_PEROXISOMEEER8.4294e-04-0.1472image
chr1:220057885-220059362:-LUSCGSVA_HALLMARK_FATTY_ACID_METABOLISMEER5.4932e-03-0.1244image
ENSG00000162813.16,BPNT1LUSCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG5.9340e-03-0.1233image
ENSG00000162813.16,BPNT1MESOGSVA_HALLMARK_P53_PATHWAYEAG1.5329e-02-0.2670image
chr1:220057885-220059362:-MESOGSVA_HALLMARK_P53_PATHWAYEER2.1836e-02-0.2530image
ENSG00000162813.16,BPNT1OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.8659e-09-0.3360image
chr1:220057885-220059362:-OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.2620e-09-0.3408image
ENSG00000162813.16,BPNT1PAADGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG6.8442e-04-0.2529image
chr1:220057885-220059362:-PAADGSVA_HALLMARK_TGF_BETA_SIGNALINGEER6.5984e-04-0.2536image
ENSG00000162813.16,BPNT1PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.2491e-12-0.4887image
chr1:220057885-220059362:-PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER1.5039e-12-0.4921image
ENSG00000162813.16,BPNT1PRADGSVA_HALLMARK_HEME_METABOLISMEAG3.4525e-17-0.3659image
chr1:220057885-220059362:-PRADGSVA_HALLMARK_HEME_METABOLISMEER3.4525e-17-0.3659image
ENSG00000162813.16,BPNT1READGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG3.7909e-03-0.2943image
chr1:220057885-220059362:-READGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.7909e-03-0.2943image
ENSG00000162813.16,BPNT1SARCGSVA_HALLMARK_COAGULATIONEAG3.8545e-020.1291image
chr1:220057885-220059362:-SARCGSVA_HALLMARK_COAGULATIONEER3.4177e-020.1322image
ENSG00000162813.16,BPNT1SKCMGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.8678e-10-0.2902image
chr1:220057885-220059362:-SKCMGSVA_HALLMARK_PROTEIN_SECRETIONEER1.8247e-10-0.2904image
ENSG00000162813.16,BPNT1STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.2623e-05-0.2192image
chr1:220057885-220059362:-STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.1999e-05-0.2196image
ENSG00000162813.16,BPNT1TGCTGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.6704e-06-0.3726image
chr1:220057885-220059362:-TGCTGSVA_HALLMARK_PROTEIN_SECRETIONEER1.8202e-06-0.3713image
ENSG00000162813.16,BPNT1THCAGSVA_HALLMARK_HEME_METABOLISMEAG1.2904e-12-0.3091image
chr1:220057885-220059362:-THCAGSVA_HALLMARK_HEME_METABOLISMEER1.4118e-12-0.3085image
ENSG00000162813.16,BPNT1THYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.6537e-09-0.5070image
chr1:220057885-220059362:-THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER4.4165e-09-0.5077image
chr1:220057885-220059362:-UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER1.2928e-06-0.3574image
ENSG00000162813.16,BPNT1UCECGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.5157e-06-0.3552image
chr1:220057885-220059362:-UVMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.5632e-02-0.2591image
ENSG00000162813.16,BPNT1UVMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.5632e-02-0.2591image


Top

7. Enriched editing regions and drugs for BPNT1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr1:220057885-220059362:-ACCLFM.A13EER4.4674e-02-0.2295image
ENSG00000162813.16,BPNT1ACCLFM.A13EAG4.4674e-02-0.2295image
chr1:220057885-220059362:-BLCAEmbelinEER1.2356e-040.1896image
ENSG00000162813.16,BPNT1BLCAEmbelinEAG1.0955e-040.1910image
chr1:220057885-220059362:-BRCAJNK.Inhibitor.VIIIEER1.1972e-050.1328image
ENSG00000162813.16,BPNT1BRCAJNK.Inhibitor.VIIIEAG1.0043e-050.1340image
chr1:220057885-220059362:-CESCAZD6482EER8.5608e-080.3012image
ENSG00000162813.16,BPNT1CESCAZD6482EAG8.7390e-080.3010image
ENSG00000162813.16,BPNT1CHOLGefitinibEAG1.1965e-03-0.5252image
chr1:220057885-220059362:-CHOLGefitinibEER1.1965e-03-0.5252image
chr1:220057885-220059362:-COADBMS.509744EER2.4088e-070.3092image
ENSG00000162813.16,BPNT1COADBMS.509744EAG2.4088e-070.3092image
chr1:220057885-220059362:-DLBCAICAREER3.9437e-050.5569image
ENSG00000162813.16,BPNT1DLBCAICAREAG3.8043e-050.5578image
ENSG00000162813.16,BPNT1ESCAFH535EAG1.3291e-020.1948image
chr1:220057885-220059362:-ESCAFH535EER1.3279e-020.1948image
chr1:220057885-220059362:-GBMKU.55933EER1.2524e-03-0.2477image
ENSG00000162813.16,BPNT1GBMKU.55933EAG1.2524e-03-0.2477image
ENSG00000162813.16,BPNT1HNSCDMOGEAG3.2925e-090.2609image
chr1:220057885-220059362:-HNSCDMOGEER3.7849e-090.2599image
chr1:220057885-220059362:-KICHEtoposideEER1.9208e-020.2920image
ENSG00000162813.16,BPNT1KICHEtoposideEAG1.9208e-020.2920image
chr1:220057885-220059362:-KIRCEmbelinEER1.0931e-120.3531image
ENSG00000162813.16,BPNT1KIRCEmbelinEAG1.0931e-120.3531image
chr1:220057885-220059362:-KIRPAZD6244EER1.3443e-12-0.4018image
ENSG00000162813.16,BPNT1KIRPAZD6244EAG1.3443e-12-0.4018image
chr1:220057885-220059362:-LAMLCisplatinEER4.2454e-020.2432image
ENSG00000162813.16,BPNT1LAMLCisplatinEAG4.2454e-020.2432image
chr1:220057885-220059362:-LGGAZD6482EER3.8221e-090.2526image
ENSG00000162813.16,BPNT1LGGAZD6482EAG3.2317e-090.2537image
chr1:220057885-220059362:-LIHCGDC.0449EER6.3198e-10-0.3139image
ENSG00000162813.16,BPNT1LIHCGDC.0449EAG2.4716e-09-0.3033image
ENSG00000162813.16,BPNT1LUADAMG.706EAG2.1864e-04-0.1628image
chr1:220057885-220059362:-LUADAMG.706EER2.1259e-04-0.1631image
ENSG00000162813.16,BPNT1LUSCLenalidomideEAG1.0231e-02-0.1151image
chr1:220057885-220059362:-LUSCLenalidomideEER9.2239e-03-0.1167image
ENSG00000162813.16,BPNT1MESOAMG.706EAG4.3336e-02-0.2237image
chr1:220057885-220059362:-MESOAMG.706EER4.2631e-02-0.2245image
ENSG00000162813.16,BPNT1OVBexaroteneEAG4.6504e-080.3130image
chr1:220057885-220059362:-OVBexaroteneEER3.1678e-080.3167image
ENSG00000162813.16,BPNT1PAADAMG.706EAG2.2102e-03-0.2312image
chr1:220057885-220059362:-PAADEHT.1864EER2.2129e-03-0.2318image
ENSG00000162813.16,BPNT1PCPGAZD.2281EAG3.9176e-08-0.3924image
chr1:220057885-220059362:-PCPGAZD.2281EER3.4257e-08-0.3940image
ENSG00000162813.16,BPNT1PRADBMS.536924EAG5.8796e-10-0.2740image
chr1:220057885-220059362:-PRADBMS.536924EER5.8796e-10-0.2740image
ENSG00000162813.16,BPNT1READBI.D1870EAG9.3692e-030.2653image
chr1:220057885-220059362:-READBI.D1870EER9.3692e-030.2653image
ENSG00000162813.16,BPNT1SARCBMS.509744EAG9.8573e-05-0.2405image
chr1:220057885-220059362:-SARCBMS.509744EER9.3885e-05-0.2412image
ENSG00000162813.16,BPNT1SKCMBMS.509744EAG1.3369e-06-0.2222image
chr1:220057885-220059362:-SKCMBMS.509744EER1.3552e-06-0.2221image
ENSG00000162813.16,BPNT1STADBMS.708163EAG2.1110e-03-0.1600image
chr1:220057885-220059362:-STADBMS.708163EER2.2210e-03-0.1592image
ENSG00000162813.16,BPNT1TGCTFH535EAG1.0920e-050.3441image
chr1:220057885-220059362:-TGCTFH535EER1.1063e-050.3439image
ENSG00000162813.16,BPNT1THCABMS.708163EAG3.4957e-100.2748image
chr1:220057885-220059362:-THCABMS.708163EER3.9586e-100.2740image
ENSG00000162813.16,BPNT1THYMBMS.509744EAG1.6484e-10-0.5457image
chr1:220057885-220059362:-THYMBMS.509744EER1.3615e-10-0.5478image
chr1:220057885-220059362:-UCECFH535EER9.6259e-040.2481image
ENSG00000162813.16,BPNT1UCECAZD6244EAG9.8412e-04-0.2484image
ENSG00000162813.16,BPNT1UCSAZD6482EAG7.3730e-030.3544image
chr1:220057885-220059362:-UCSAZD6482EER7.3730e-030.3544image
chr1:220057885-220059362:-UVMGSK269962AEER2.4589e-03-0.3667image
ENSG00000162813.16,BPNT1UVMGSK269962AEAG2.4589e-03-0.3667image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType